

Filed: June 8, 2018

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.

Petitioner

v.

POZEN INC. and HORIZON PHARMA USA, INC.

Patent Owners

Case No. IPR2017-01995
U.S. Patent No. 9,220,698

PETITIONER'S OBJECTIONS TO PATENT OWNERS' EVIDENCE

Pursuant to 37 C.F.R. § 42.64(b)(1), Petitioner Mylan Pharmaceuticals Inc. (“Petitioner”) objects to the admissibility of the following exhibits filed by Patent Owners Pozen Inc. and Horizon Pharma USA, Inc. (“Patent Owners”) in the Patent Owners’ Response in the above-captioned *inter partes* review.

Petitioner’s objections are timely under 37 C.F.R. § 42.64(b)(1) because they are being filed and served within five business days. Petitioner’s objections provide notice to Patent Owners that Petitioner may move to exclude these exhibits under 37 C.F.R. § 42.64(c).

In this paper, a reference to “FRE” means the Federal Rules of Evidence, a reference to “CFR” means the Code of Federal Regulations, and “’698 patent” means U.S. Patent No. 9,220,698. All objections under FRE 801-803 (hearsay) apply to the extent Patent Owners rely on the exhibits identified in connection with that objection for the truth of the matter asserted therein.

Exhibit descriptions provided in this table are taken from Patent Owners’ exhibit list and are used for identification purposes only. The use of the description does not indicate that Petitioner agrees with the descriptions or characterizations of the documents.

Exhibit	Description	Objection
2012	Gabriel, S.E., et al., <i>Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs</i> , <i>Annals of Internal Medicine</i> , Vol. 115, No. 10, pp. 787-796 (1991) (with publication information)	A, D, F, G, H, M, N, O

Exhibit	Description	Objection
2013	Cryer, B. and Feldman, M., <i>Effects of Nonsteroidal Anti-inflammatory Drugs on Endogenous Gastrointestinal Prostaglandins and Therapeutic Strategies for Prevention and Treatment of Nonsteroidal Anti-inflammatory Drug-Induced Damage</i> , Archives of Internal Medicine, Vol. 152, pp. 1145-1155 (1992) (with publication information)	A, D, F, G, H, M, N, O
2014	Fries, J.F., et al., <i>Nonsteroidal Anti-Inflammatory Drug-Associated Gastropathy: Incidence and Risk Factor Models</i> , The American Journal of Medicine, Vol. 91, pp. 213-222 (1991) (with publication information)	A, D, F, G, H, M, N, O
2015	Jan. 12, 2017 Trial Testimony of John R. Plachetka in the <i>Horizon Pharma, Inc. v. Dr. Reddy's Laboratories, Inc.</i> , Case No. 3:11-cv- 02317 (D.N.J.)	A, B, C, D, E, F, G, H, I, J, M, N, O, W
2016	Jan. 24, 2018 Deposition Testimony of Dr. John R. Plachetka in the <i>Horizon Pharma, Inc. v. Dr. Reddy's Laboratories, Inc.</i> , Case No. 3:15-cv-03324 (D.N.J.) PROTECTIVE ORDER MATERIAL	A, B, C, D, E, F, G, H, I, J, M, N, O, W
2017	PN400-104 Clinical Study Report PROTECTIVE ORDER MATERIAL	A, B, C, D, E, F, I, M, N, O
2018	Oct. 12, 2017 Deposition Testimony of Everardus Orlemans, Ph.D. in the <i>Horizon Pharma, Inc. v. Dr. Reddy's Laboratories, Inc.</i> , Case No. 3:15-cv-03324 (D.N.J.)	A, B, C, D, E, F, G, H, I, J, M, N, O, W
2019	Oct. 27, 2017 Deposition Testimony of Mark Sostek, MD in the <i>Horizon Pharma, Inc. v. Dr. Reddy's Laboratories, Inc.</i> , Case No. 3:15-cv-03324 (D.N.J.) PROTECTIVE ORDER MATERIAL	A, B, C, D, E, F, G, H, I, J, M, N, O, W
2020	Oct. 25, 2017 Deposition Testimony of Brian Ault, Ph.D. in the <i>Horizon Pharma, Inc. v. Dr. Reddy's Laboratories, Inc.</i> , Case No. 3:15-cv-03324 (D.N.J.) PROTECTIVE ORDER MATERIAL	A, B, C, D, E, F, G, H, I, J, M, N, O, W

Exhibit	Description	Objection
2021	Norman, A. and Hawkey, C.J., <i>What you need to know when you prescribe a proton pump inhibitor</i> , Frontline Gastroenterology, Vol. 2, pp. 199-205 (2011)	A, C, D, E, F, G, H, M, N, O
2022	Stollman, N. and Metz, D.C., <i>Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients</i> , J. Critical Care, Vol. 20, pp. 35-45 (2005)	A, D, F, G, H, M, N, O
2023	Declaration of Michael Mayersohn, Ph.D. in Support of Defendants' Claim Construction Brief filed on April 24, 2014 in <i>Par Pharm., Inc. v. Takeda Pharm. Co.</i> , Case No. 5:13-CV-1927 LHK (PSG)	A, B, C, D, E, F, G, H, I, M, N, O
2024	January 30, 2013 Amendment C and Response to Final Office Action, Application No. 12/553,107	A, I, M, N, O
2025	Declaration of David R. Taft PH.D. In Support of Patent Owner Response to Petition for <i>Inter Partes</i> Review of U.S. Patent No. 9,220,698	A, D, F, G, H, I, N, O, Q, S, T, U
2026	Declaration of David A. Johnson. M.D. In Support of Patent Owner Response to Petition for <i>Inter Partes</i> Review of U.S. Patent No. 9,220,698	A, D, F, G, H, I, N, O, Q, S, T, U
2027	IPR2017-01995, May 25, 2018 Deposition Transcript of David C. Metz	A, B, D, F, G, H, I, K, L, M, N, O, Q, S, T, U
2028	Redacted Amended Memorandum Opinion (D.I. 498), Case 3:11-cv- 02317-MLC-DEA (D.N.J. July 12, 2017)	A, C, E, I, M, N, O
2029	IPR2017-01995, May 24, 2018 Deposition Transcript of Dr. Michael Mayersohn	A, B, D, F, G, H, I, K, L, M, N, O, Q, S, T, U
2030	Oct. 16, 2014 Deposition Testimony of Brian Ault, Ph.D. in the <i>Horizon Pharma, Inc. v. Dr. Reddy's Laboratories, Inc.</i> , Case No. 3:11-cv-02317 (D.N.J.) PROTECTIVE ORDER MATERIAL	A, B, C, D, E, F, G, H, I, J, M, N, O, W

Exhibit	Description	Objection
2031	Oct. 10, 2014 Deposition Testimony of Dr. Mark Sostek in the <i>Horizon Pharma, Inc. v. Dr. Reddy's Laboratories, Inc.</i> , Case No. 3:11-cv-02317 (D.N.J.) PROTECTIVE ORDER MATERIAL	A, B, C, D, E, F, G, H, I, J, M, N, O, W
2032	Email string from Tore Lind to Richard Leff, Doug Levine, David Magner, and Mark Sostek, dated May 27, 2006 to May 31, 2006	A, B, D, F, I, J, K, M, N, O, R
2033	Andersson et al., <i>Pharmacokinetic Studies with Esomeprazole, the (S)- Isomer of Omeprazole</i> , CLIN. PHARMACOKINET., 40(6):411-426 (2001)	A, D, F, G, H, M, N, O
2034	Tolman et al., <i>The Effects of Oral Doses of Lansoprazole and Omeprazole on Gastric pH</i> , J. CLIN. GASTROENTEROL., 24(2):65-70 (1997)	A, D, F, G, H, M, N, O
2035	Hartmann et al., <i>Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole</i> , ALIMENT PHARMACOL. THER., 10:359-366 (1996)	A, D, F, G, H, M, N, O
2036	Leucuta et al., <i>Pharmacokinetics and Metabolic Drug Interactions</i> , CURRENT CLINICAL PHARMACOLOGY, 1:5-20 (2006)	A, D, F, G, H, M, N, O
2037	Meyer, <i>Interaction of Proton Pump Inhibitors with Cytochromes P450: Consequences for Drug Interactions</i> , YALE J. BIOL. MED., 69:203-209 (1996)	A, D, F, G, H, M, N, O
2038	Prilosec Label	A, C, E, M, N, O
2039	Vanderhoff et al., <i>Proton Pump Inhibitors: An Update</i> , AMERICAN FAMILY PHYSICIAN, 66:273-280 (2002)	A, D, F, G, H, M, N, O
2040	Arnold, <i>Safety of proton pump inhibitors-an overview</i> , Aliment Pharmacol. Ther., 8(Suppl. 1):65-70 (1994)	A, D, F, G, H, M, N, O
2041	VIMOVO Prescribing Information	A, B, C, D, E, F, H, M, N, O

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.